Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company dedicated to developing therapies for neurodegenerative diseases, has announced the appointment of Neil Berkley as Chief Financial Officer (CFO) and Chief Business Officer (CBO), effective December 10, 2025. Berkley, who has served as Alector’s CBO since March 2024 and held the interim CFO position since June 2025, will maintain his role as CBO alongside his new responsibilities as CFO.

Alector's CEO, Arnon Rosenthal, commended Berkley for his exceptional leadership and strategic insight, emphasizing his vital role in driving the company’s mission forward. With over two decades of experience in the biotech field, Berkley brings a robust background in corporate strategy, finance, and business development, having held significant positions in various pharmaceutical and biotechnology companies. His tenure at Alector has notably included advancing the company’s strategic priorities and enhancing partnerships, which are essential for value creation.

Berkley expressed his honor in taking on the CFO role, highlighting the privilege of working with a dedicated team focused on delivering transformative therapies for patients with neurodegenerative diseases. He underscored his commitment to supporting Alector’s scientific initiatives and the development of its promising pipeline, including their proprietary Alector Brain Carrier (ABC) platform, which aims to improve the delivery and efficacy of therapeutics targeting conditions such as Alzheimer’s disease and Parkinson's disease.

Alector remains headquartered in South San Francisco and continues to focus on leveraging genetic, immunological, and neuroscientific principles to combat the progression of neurodegenerative diseases. For further information, visit their website at www.alector.com.

Alector's recent appointment of Neil Berkley as Chief Financial Officer (CFO) while maintaining his role as Chief Business Officer (CBO) signals a strategic move at a critical juncture for the company. With Berkley’s extensive experience across various biotech stages and his understanding of Alector’s mission, market sentiment could be positively affected, potentially leading to a favorable environment for investors.

Berkley’s dual role suggests that Alector is not just focused on short-term financial management but is also actively aligning its financial strategy with its broader business development goals, particularly as it advances its pipeline of therapies targeting neurodegenerative diseases. The emphasis on strategic partnerships and the company's commitment to innovative therapies could bolster investor confidence, especially as the healthcare sector increasingly values synergistic R&D collaborations.

Alector’s focus on leveraging its proprietary Alector Brain Carrier (ABC) platform to enhance drug delivery systems may also appeal to investors looking for companies at the forefront of biotechnology innovation. The ability to efficiently navigate through complex clinical stages while ensuring lower costs and improved patient outcomes positions Alector favorably in a competitive market.

Given the surge in interest surrounding neurodegenerative treatments, Alector has the potential to attract further investment, particularly if the company can demonstrate progress in its clinical trials. Investors may want to keep an eye on Alector's future announcements, particularly any updates on their pipeline development and strategic partnerships, as these could serve as catalysts for stock performance.

In summary, Alector appears well-positioned for continued growth under Berkley’s leadership. Long-term investors might see this as an opportune time to consider positions, especially if the stock remains undervalued relative to its innovation potential and market trajectory. However, all investments in clinical-stage biotechnology should be approached with caution due to inherent risks.